Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -

Trial Profile

Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 29 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 Planned End Date changed from 31 Dec 2017 to 1 Dec 2017.
    • 29 Jan 2017 Primary endpoint (Change from baseline in weekly mean SBM frequency during one week of administration (Part I)) has been met, according to Astellas Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top